secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-06-24T23:59:59+00:00
Accession:  0001816590-22-000066
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

PTAB denies post-grant review of two Compass Pathways patents
-------------------------------------------------------------

- Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.
- Freedom to Operate had filed petitions challenging patentability on three grounds: improper subject matter, obviousness, and lack of enablement.
- Decision upholds validity of key patents covering COMPASS's psilocybin-related intellectual property.
- Outcome removes near-term patent invalidation risk for Compass Pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/0001816590-22-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/cmps-20220622.htm
  HTML page:      https://secwatch.observer/filing/0001816590-22-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer